THE DIRECTORS OF IGRAINE PLC CONSIDER THIS ANNOUNCEMENT TO CONTAIN INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO. 594/2014 OF THE EUROPEAN PARLIAMENT AND THE COUNCIL OF 16 APRIL 2014 ON MARKET ABUSE AS IT FORMS PART OF RETAINED EU LAW AS DEFINED IN THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. BY PUBLICATION OF THIS ANNOUNCEMENT, THE INFORMATION SET OUT WITHIN IT IS DEEMED NOW TO BE IN THE PUBLIC DOMAIN.
26 September 2025
Igraine Plc
(“Igraine” or “the Company”)
Interim Results for the Half-Year to 30 June 2025
Igraine plc, Directors Statement,
Igraine Plc, the investment issuer focused on opportunities within the alternative energy and the life sciences and breakthrough technologies sectors is pleased to announce its unaudited interim results for the six-month period ended 30 June 2025. These interim results reflect the Company’s ongoing investment activities and financial position during the period under review. The Board continues to monitor opportunities aligned with Igraine’s investment strategy and will update shareholders as appropriate.
The interim financial statements for the 6 months ended 30 June 2025 have not been reviewed or audited.
On behalf of the Board
David Levis
Director and Chief Executive Officer
The Directors of the Company, who have issued this RIS announcement after due and careful enquiry, accept responsibility for its content.
Enquiries
Company:
David Levis (Chief Executive Officer)
Investor relations : info@igraineplc.com
AQSE Growth Market Corporate Adviser
Peterhouse Capital Limited
Guy Miller / Mark Anwyl
Tel: +44 (0) 207 469 0930
INTERIM INCOME STATEMENT (UNAUDITED)
For the period ended 30 June 2025
Igraine plc
6 mths to
6 mths to
30 June
30 June
2025
2024
£ GBP
£ GBP
Revenue
-
-
Cost of Sales
-
-
Gross Profit/(Loss)
-
-
Other Operating Income
13,448
-
Gain/(Loss) on revaluation of investments
(34,819)
37,581
Administrative Expenses
(104,381)
(105,374)
Loss before Investment Activities
(125,752)
(67,793)
Interest income
-
391
Loss before Amortisation of Preference Shares
(125,752)
(67,402)
Loss before Taxation
(125,752)
(67,402)
Taxation Expense
-
-
Total Loss attributable to Equity Holders of the Company
(125,752)
(67,402)
STATEMENTS OF FINANCIAL POSITION (UNAUDITED)
As at 30 June 2025
Igraine plc
As at
As at
As at
30 June
31 Dec
30 June
2025
2024
2024
£ GBP
£ GBP
£ GBP
Assets
Non-current assets
Property, plant and equipment
-
-
423
Investments
57,626
92,445
234,219
Intangibles
124,288
124,288
-
181,914
216,733
234,642
Current assets
Trade and other receivables
31,566
26,363
52,519
Cash and cash equivalents
33,330
7,273
84,191
64,896
33,636
136,710
Total assets
246,810
250,369
371,352
Equity and liabilities
Equity
Issued share capital
589,495
589,495
588,785
Share Premium
2,070,410
2,070,410
1,946,995
Other reserves
46,116
46,116
46,116
Retained earnings
(2,754,656)
(2,628,904)
(2,444,785)
Total (deficit)/equity
(48,635)
77,117
137,111
Non-current liabilities
Loans and borrowings
162,102
60,133
14,806
Current liabilities
Trade and other payables
133,343
113,119
219,435
Total liabilities
295,445
173,252
234,241
Total equity and liabilities
246,810
250,369
371,352
Notes to the balance sheet
Post Balance sheet events
Subsequent to the period end the following occurred:
Fixit Medical Ltd, an investee company, completed a director financing at a subscription price of £1,150 per share, resulting in the Company’s holding being revalued at £499,100.
